Current status and limitations of immunotherapy for breast cancer
نویسندگان
چکیده
منابع مشابه
Immunotherapy for Breast Cancer Treatment
Breast cancer, as a heterogeneous disease, includes a wide range of pathological and clinical behaviors. Current treatment protocols, including radiotherapy, chemotherapy, and hormone replacement therapy, are mainly associated with poor response and high rate of recurrence. Therefore, more efforts are needed to develop alternative therapies for this type of cancer. Immunotherapy, as a novel str...
متن کاملCurrent status of cancer immunotherapy
To prove clinical benefits of cancer vaccine is currently difficult, except for one phase III trial has documented improved overall survival with the vaccine, Sipuleucel-T, although induction of anti-tumor immune responses through cancer vaccine is theoretically promising and would be straightforward. In contrast, immune checkpoint blockade with anti-CTLA4 mAb and anti-PD-1 mAb has demonstrated...
متن کاملCurrent status of vinorelbine for breast cancer.
Vinorelbine tartrate (Navelbine) is a new semisynthetic vinca alkaloid with efficacy against a variety of solid tumors, including non-small-cell lung cancer, breast cancer, head and neck cancer, and Hodgkin's lymphoma. Recently approved by the FDA for the first-line treatment of advanced non-small-cell lung cancer, vinorelbine is also under review by the FDA for use in patients with metastatic ...
متن کاملCurrent status of immunotherapy for the treatment of lung cancer.
Immunotherapy is a novel approach for the treatment of systemic malignancies. Passive and adaptive immunotherapy have been applied to the treatment of a wide variety of solid tumors such as malignant melanoma (1), renal cell carcinoma (2) and ovarian cancer (3). Several early clinical trials of immune based therapy for both non-small (NSCLC) and small cell lung cancer (SCLC) have demonstrated l...
متن کاملCloning, expression, purification and the study of immunotherapy status of TGFαL3-SEB chimeric protein in breast cancer treatment
Background & Aim: Bacterial superantigens, stimulate polyclonal T cells irrespective of their antigen specificity, resulting in a massive release of cytokines from T cells and monocytes, and suggest that that they could be candidates of new antitumor agents. Recent attempts have been done to specifically target superantigens towards tumors. Here, we evaluate TGFαL3-SEB fusion protein as a new a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Surgery
سال: 2020
ISSN: 0039-6060
DOI: 10.1016/j.surg.2019.09.018